Biopharmaceutical Company
Appears in 1 story
Developer of soficitinib, moving toward regulatory filing
Millions of people with severe eczema live with relentless itching and raw, inflamed skin. On July 15, 2026, InnoCare Pharma said its once-daily pill, soficitinib, hit the main goal of a late-stage trial in that group.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
